• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

7 diabetes treatment innovations to look out for on World Diabetes Day

November 15, 2021 By Sean Whooley

Dexcom G7 & APIs

Dexcom G7 Wearable Top (1)
Dexcom’s G7 CGM [Image from Dexcom]
Dexcom (NSDQ:DXCM) Chairman, President & CEO Kevin Sayer told Drug Delivery Business News earlier this year that the company expects to launch its next-generation G7 continuous glucose monitor (CGM) in Europe this autumn. During Dexcom’s third-quarter earnings call this month, he said the company remains on track for a fourth-quarter launch of the G7 following CE mark clearance.

When it comes to the U.S. market and the G7, Sayer expected Dexcom to make a comprehensive 510(k) submission, including G7 hardware and full Android and iOS software, to the FDA in the next few weeks. He said the U.S. clinical trial for the device has concluded.

“It’s been our experience over time when we deliver what the FDA expects, they move very quickly and are very cooperative with us,” Sayer said. “We have no reason to believe the file we’re preparing isn’t going to meet those expectations. We’re moving along those lines. So again, with the CE Mark filing, we’re on track for an [outside of U.S.] launch later this year, and we’ll update you more on the U.S. as time goes on.”

The company also announced last month that Garmin became the company’s first partner for its real-time application programming interfaces (APIs).

Garmin introduced its Dexcom Connect IQ apps on its smartwatch and cycling computer. The Dexcom Partner Web APIs enable invited third-party developers to integrate real-time continuous glucose monitoring (CGM) data into their digital health apps and devices.

Next>>

Pages: Page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8

Filed Under: Auto-injectors, Business/Financial News, Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Patient Monitoring, Pharmaceuticals Tagged With: Dexcom, Diabeloop, Eli Lilly, Eli Lilly & Co., Fractyl Health, Insulet, Medtronic, Senseonics, Twin Health

IN CASE YOU MISSED IT

  • Dexcom updates CGM receiver recall that led to serious adverse events
  • Abbott reports momentum with Libre CGM business as new dual sensor will ‘accelerate’ growth
  • Johnson & Johnson wins FDA priority review for drug delivery system
  • Glucose monitoring company LifeScan files chapter 11 to reduce debt
  • Medtronic enrolls first patient in study for Onyx liquid embolic system

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS